USO DO CANABIDIOL EM CRIANÇAS COM TRANSTORNO DO ESPECTRO AUTISTA E SINTOMAS PSIQUIÁTRICOS ASSOCIADO

Autism Spectrum Disorder (ASD) is a neurodevelopmental condition that poses complex therapeutic challenges, especially when associated with psychiatric comorbidities such as anxiety, aggression, sleep disturbances, and disruptive behaviors. Conventional treatment using psychotropic drugs often results in significant side effects, particularly in children, prompting the search for safer and more effective alternatives. In this context, cannabidiol (CBD), a non-psychoactive compound derived from Cannabis sativa, has gained prominence due to its anxiolytic, antipsychotic, and neuroprotective properties. This literature review analyzed recent scientific evidence on the use of cannabidiol in managing psychiatric symptoms in children with ASD. The findings suggest that CBD may significantly reduce aggressive behaviors, sleep disorders, and anxiety symptoms, with a favorable safety profile. However, the lack of robust, controlled clinical trials limits the generalizability of the results. It is concluded that CBD represents a promising therapeutic alternative, but its use must be guided by scientific rigor, clinical ethics, and multidisciplinary monitoring.